Progress towards a consensus on biomarkers for Alzheimer's disease: a review of peripheral analytes.

Alzheimer's disease (AD) is the most common cause of dementia in the elderly population and attempts to develop therapies have been unsuccessful because there is no means to target an effective therapeutic window. CNS biomarkers are insightful but impractical for high-throughput population-based screening. Therefore, a peripheral, blood-based biomarker for AD would significantly improve early diagnosis, potentially enable presymptomatic detection and facilitate effective targeting of disease-modifying treatments. The various constituents of blood, including plasma, platelets and cellular fractions, are now being systematically explored as a pool of putative peripheral biomarkers for AD. In this review we cover some less known peripheral biomarkers and highlight the latest developments for their clinical application.

[1]  C. Hong,et al.  Peripheral Cytokines and Chemokines in Alzheimer’s Disease , 2009, Dementia and Geriatric Cognitive Disorders.

[2]  L. Minthon,et al.  No Diagnostic Value of Plasma Clusterin in Alzheimer's Disease , 2012, PloS one.

[3]  P. Pasqualetti,et al.  Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF β-amyloid, and h-tau , 2006, Neurology.

[4]  C. Masters,et al.  Variability in blood-based amyloid-beta assays: the need for consensus on pre-analytical processing. , 2012, Journal of Alzheimer's disease : JAD.

[5]  P. Rossini,et al.  Alteration of peripheral markers of copper homeostasis in Alzheimer's disease patients: implications in aetiology and therapy. , 2007, The journal of nutrition, health & aging.

[6]  S. Tsuji,et al.  The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta 42(43) , 1997, Neurology.

[7]  B. Hyman,et al.  Plasma Amyloid and the Risk of Alzheimer Disease and Dementia in Elderly Men , 2008 .

[8]  D. Holtzman,et al.  Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease , 2008, Nature.

[9]  J. Thome,et al.  Proteomic research in psychiatry , 2011, Journal of psychopharmacology.

[10]  F. Jessen,et al.  Amyloid β peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing , 2010, Experimental Neurology.

[11]  Deborah Pinchev,et al.  Mining biomarkers in human sera using proteomic tools , 2004, Proteomics.

[12]  E. Oguni,et al.  Amyloid β protein in plasma from patients with sporadic Alzheimer's disease , 1996, Journal of the Neurological Sciences.

[13]  Tracy R. Keeney,et al.  From SOMAmer-Based Biomarker Discovery to Diagnostic and Clinical Applications: A SOMAmer-Based, Streamlined Multiplex Proteomic Assay , 2011, PloS one.

[14]  T. Lehtimäki,et al.  Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease , 2004, Human Genetics.

[15]  Patrick L. McGeer,et al.  Inflammatory processes in Alzheimer's disease , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[16]  F. Jiménez-Jiménez,et al.  Cerebrospinal fluid levels of transition metals in patients with Alzheimer's disease , 1998, Journal of Neural Transmission.

[17]  W. Thies,et al.  2008 Alzheimer’s disease facts and figures , 2008, Alzheimer's & Dementia.

[18]  N. Robakis,et al.  Increased Expression but Reduced Activity of Antioxidant Enzymes in Alzheimer's Disease. , 1999, Journal of Alzheimer's disease : JAD.

[19]  C. Masters,et al.  Overexpression of Alzheimer's Disease Amyloid-β Opposes the Age-dependent Elevations of Brain Copper and Iron* , 2002, The Journal of Biological Chemistry.

[20]  V. Haroutunian,et al.  Elevated cortical zinc in Alzheimer disease , 2006, Neurology.

[21]  T. Miida,et al.  [Lipoproteins and their receptors in the central nervous system]. , 2009, Rinsho byori. The Japanese journal of clinical pathology.

[22]  K. Yaffe,et al.  The projected effect of risk factor reduction on Alzheimer's disease prevalence , 2011, The Lancet Neurology.

[23]  C. Rowe,et al.  Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging. , 2010, Journal of Alzheimer's disease : JAD.

[24]  Peripheral Mitochondrial Dysfunction in Alzheimer’s Disease: Focus on Lymphocytes , 2012, Molecular Neurobiology.

[25]  J. Eaton,et al.  Hemoglobin. A biologic fenton reagent. , 1984, The Journal of biological chemistry.

[26]  P. Mcgeer,et al.  Thrombin accumulation in brains of patients with Alzheimer's disease , 1992, Neuroscience Letters.

[27]  D. Selkoe,et al.  Alzheimer's Disease: A Central Role for Amyloid , 1994, Journal of neuropathology and experimental neurology.

[28]  Justin Bedo,et al.  Blood-based protein biomarkers for diagnosis of Alzheimer disease. , 2012, Archives of neurology.

[29]  R. W. Gracy,et al.  Identification of oxidized plasma proteins in Alzheimer's disease. , 2002, Biochemical and biophysical research communications.

[30]  N. Inestrosa,et al.  Postsynaptic Receptors for Amyloid-β Oligomers as Mediators of Neuronal Damage in Alzheimer’s Disease , 2012, Front. Physio..

[31]  T. Berzin,et al.  Microvascular injury and blood–brain barrier leakage in Alzheimer's disease , 2007, Neurobiology of Aging.

[32]  Guanghua Xiao,et al.  A Blood-Based Screening Tool for Alzheimer's Disease That Spans Serum and Plasma: Findings from TARC and ADNI , 2011, PloS one.

[33]  A. Fagan,et al.  Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease , 2009, EMBO molecular medicine.

[34]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[35]  P. Pasqualetti,et al.  Copper in Alzheimer's disease: a meta-analysis of serum,plasma, and cerebrospinal fluid studies. , 2011, Journal of Alzheimer's disease : JAD.

[36]  R. Mayeux,et al.  APOE genotype, plasma lipids, lipoproteins, and AD in community elderly , 1999, Neurology.

[37]  B. Hyman,et al.  APOE ε3/ε4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer’s disease diagnosis , 2003, Experimental Neurology.

[38]  A. Nicholson,et al.  Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. , 2009, The Journal of thoracic and cardiovascular surgery.

[39]  J. Growdon,et al.  Evidence for a membrane defect in Alzheimer disease brain. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[41]  Nick C Fox,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes , 2009, Nature Genetics.

[42]  P. Pasqualetti,et al.  Excess of serum copper not related to ceruloplasmin in Alzheimer disease , 2005, Neurology.

[43]  G. Rebeck,et al.  Regulated Proteolysis of APP and ApoE Receptors , 2008, Molecular Neurobiology.

[44]  P. Pasqualetti,et al.  Elevation of serum copper levels discriminates Alzheimer’s disease from vascular dementia , 2003, Neurology.

[45]  S. Kang,et al.  Nuclear clusterin is associated with neuronal apoptosis in the developing rat brain upon ethanol exposure. , 2012, Alcoholism, clinical and experimental research.

[46]  A. Thomson,et al.  Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: riboregulation against neural oxidative damage in Alzheimer's disease. , 2008, Biochemical Society transactions.

[47]  Qian-Li Xue,et al.  Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study. , 2007, Archives of neurology.

[48]  J. Growdon,et al.  Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels , 2003 .

[49]  C. Mariani,et al.  Plasma levels of beta-amyloid (1–42) in Alzheimer's disease and mild cognitive impairment , 2006, Neurobiology of Aging.

[50]  B. Sedighi,et al.  A study of serum copper and ceruloplasmin in Alzheimer's disease in Kerman, Iran , 2006 .

[51]  Sudha Seshadri,et al.  Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. , 2003, Archives of internal medicine.

[52]  C. Rowe,et al.  Increasing the predictive accuracy of amyloid-β blood-borne biomarkers in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[53]  D. Butterfield,et al.  Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease. , 2008, Biochimica et biophysica acta.

[54]  V. Papadopoulos,et al.  Oxidative stress-mediated DHEA formation in Alzheimer’s disease pathology , 2003, Neurobiology of Aging.

[55]  J. Gutteridge,et al.  The antioxidant activity of haptoglobin towards haemoglobin-stimulated lipid peroxidation. , 1987, Biochimica et biophysica acta.

[56]  Michael I. Miller,et al.  Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss , 2010, Alzheimer's & Dementia.

[57]  M. Mattson,et al.  Aβ25–35 induces rapid lysis of red blood cells: contrast with Aβ1–42 and examination of underlying mechanisms , 1997, Brain Research.

[58]  K. Blennow,et al.  Altered Distribution of the Gangliosides GM1 and GM2 in Alzheimer’s Disease , 2012, Dementia and Geriatric Cognitive Disorders.

[59]  P. He,et al.  Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/mass spectrometry. , 2010, Clinical biochemistry.

[60]  L. Buée,et al.  Association of plasma amyloid β with risk of dementia , 2009, Neurology.

[61]  P. Rossini,et al.  Ceruloplasmin fragmentation is implicated in 'free' copper deregulation of Alzheimer disease , 2008, Prion.

[62]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[63]  K. Dross,et al.  Concentration and origin of choline in the rat brain , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[64]  J. Benito-León,et al.  Cerebrospinal fluid levels of non-neurotransmitter amino acids in patients with Alzheimer's disease , 1998, Journal of Neural Transmission.

[65]  P. Ince,et al.  Mitochondrial enzyme-deficient hippocampal neurons and choroidal cells in AD , 2001, Neurology.

[66]  S. Lovestone,et al.  Proteome-based plasma biomarkers for Alzheimer's disease. , 2006, Brain : a journal of neurology.

[67]  Colin L Masters,et al.  Gene knockout of amyloid precursor protein and amyloid precursor‐like protein‐2 increases cellular copper levels in primary mouse cortical neurons and embryonic fibroblasts , 2004, Journal of neurochemistry.

[68]  M. Muckenthaler,et al.  Altered serum iron and copper homeostasis predicts cognitive decline in mild cognitive impairment. , 2012, Journal of Alzheimer's disease : JAD.

[69]  M. Pras,et al.  Apolipoprotein E Carboxyl-terminal Fragments Are Complexed to Amyloids A and L , 1995, The Journal of Biological Chemistry.

[70]  M. Sabbagh,et al.  Potential Peripheral Biomarkers for the Diagnosis of Alzheimer's Disease , 2011, International journal of Alzheimer's disease.

[71]  Tamara B Harris,et al.  Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. , 2011, JAMA.

[72]  T. Yagi,et al.  Cadherin-related Neuronal Receptors in Incisor Development , 2003, Journal of dental research.

[73]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[74]  K. Blennow,et al.  Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma , 2000, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[75]  L. Pike.  The challenge of lipid rafts This work was supported by National Institutes of Health grants RO1 GM064491 and R01 GM082824 to LJP. Published, JLR Papers in Press, October 27, 2008. , 2009, Journal of Lipid Research.

[76]  Xianlin Han,et al.  Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis , 2002, Journal of neurochemistry.

[77]  C. Masters,et al.  Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice , 1999, Brain Research.

[78]  G. Jicha,et al.  Blood serum miRNA: Non-invasive biomarkers for Alzheimer's disease , 2012, Experimental Neurology.

[79]  C. Laske,et al.  Amyloid-β peptides in plasma and cognitive decline after 1 year follow-up in Alzheimer's disease patients. , 2010, Journal of Alzheimer's disease : JAD.

[80]  J. Growdon,et al.  Plasma F2A Isoprostane Levels in Alzheimer’s and Parkinson’s Disease , 2007, Neurodegenerative Diseases.

[81]  J. Escanero,et al.  Serum aluminum levels in alzheimer’s disease and other senile dementias , 2007, Biological Trace Element Research.

[82]  R. Mayeux,et al.  Plasma A&bgr;40 and A&bgr;42 and Alzheimer’s disease: Relation to age, mortality, and risk , 2003 .

[83]  H. Möller,et al.  A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients , 2000, Neurobiology of Aging.

[84]  J. Trojanowski,et al.  Increased 8,12‐iso‐iPF2α‐VI in Alzheimer's disease: Correlation of a noninvasive index of lipid peroxidation with disease severity , 2000, Annals of neurology.

[85]  E. B. Larson,et al.  Serum cholesterol and risk of Alzheimer disease , 2005, Neurology.

[86]  P. Moscato,et al.  Differences in Abundances of Cell-Signalling Proteins in Blood Reveal Novel Biomarkers for Early Detection Of Clinical Alzheimer's Disease , 2011, PloS one.

[87]  Antonio Lanzirotti,et al.  Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer's disease. , 2006, Journal of structural biology.

[88]  R. Mayeux,et al.  Change in plasma Aβ peptides and onset of dementia in adults with Down syndrome , 2010, Neurology.

[89]  M. Muckenthaler,et al.  Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. , 2009, Journal of Alzheimer's disease : JAD.

[90]  B. Winblad,et al.  Abnormal platelet amyloid-β protein precursor (AβPP) metabolism in Alzheimer's disease: identification and characterization of a new AβPP isoform as potential biomarker. , 2013, Journal of Alzheimer's disease : JAD.

[91]  A. Fagan,et al.  Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research , 2015, Alzheimer's & Dementia.

[92]  P. Sachdev,et al.  Plasma biomarkers for mild cognitive impairment and Alzheimer's disease , 2009, Brain Research Reviews.

[93]  R. Kalaria,et al.  Serine protease inhibitor antithrombin III and its messenger RNA in the pathogenesis of Alzheimer's disease. , 1993, The American journal of pathology.

[94]  G. Kemmler,et al.  Plasma amyloid β protein 42 in non-demented persons aged 75 years: Effects of concomitant medication and medial temporal lobe atrophy , 2005, Neurobiology of Aging.

[95]  C. Lyketsos,et al.  Serum ceramides increase the risk of Alzheimer disease , 2012, Neurology.

[96]  C. Jack,et al.  Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI , 2011, Acta Neuropathologica.

[97]  Nick C Fox,et al.  Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .

[98]  K. Blennow,et al.  Evolution of Aβ42 and Aβ40 levels and Aβ42/Aβ40 ratio in plasma during progression of Alzheimer’s disease: A multicenter assessment , 2009 .

[99]  N. Inestrosa,et al.  Platelets Are the Primary Source of Amyloid β-Peptide in Human Blood , 1995 .

[100]  I. Kloszewska,et al.  Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. , 2005, Acta neurobiologiae experimentalis.

[101]  I. Björkhem,et al.  Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain , 2006, Journal of internal medicine.

[102]  Xianlin Han,et al.  Metabolomics in Early Alzheimer's Disease: Identification of Altered Plasma Sphingolipidome Using Shotgun Lipidomics , 2011, PloS one.

[103]  K. Blennow,et al.  Inflammatory Markers in Matched Plasma and Cerebrospinal Fluid from Patients with Alzheimer’s Disease , 2003, Dementia and Geriatric Cognitive Disorders.

[104]  P. Grammas,et al.  Thrombin, a mediator of neurotoxicity and memory impairment , 2004, Neurobiology of Aging.

[105]  R. Wyatt,et al.  Cerebrospinal fluid protein variations in common to Alzheimer's disease and schizophrenia. , 1992, Applied and theoretical electrophoresis : the official journal of the International Electrophoresis Society.

[106]  A. Hofman,et al.  Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study , 2006, The Lancet Neurology.

[107]  C. Masters,et al.  Inhibition of γ‐secretase causes increased secretion of amyloid precursor protein C‐terminal fragments in association with exosomes , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[108]  R. Petersen,et al.  Association of Low Plasma Aβ42/Aβ40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease , 2007 .

[109]  P. Panegyres,et al.  Genetic testing for Alzheimer's disease , 2000, The Medical journal of Australia.

[110]  Solve Sæbø,et al.  A gene expression pattern in blood for the early detection of Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[111]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[112]  Tony Wyss-Coray,et al.  Inflammation in Neurodegenerative Disease—A Double-Edged Sword , 2002, Neuron.

[113]  S. Lovestone,et al.  Plasma biomarkers for Alzheimer's disease: much needed but tough to find. , 2012, Biomarkers in medicine.

[114]  Pedro Pesini,et al.  Reliable Measurements of the β-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD , 2012, International journal of Alzheimer's disease.

[115]  B. Festoff,et al.  Serine proteases and their serpin inhibitors in Alzheimer's disease. , 1994, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[116]  P. Mehta,et al.  Amyloid β protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease , 2001, Neuroscience Letters.

[117]  D. Galimberti,et al.  Immunotherapy against amyloid pathology in Alzheimer's disease , 2013, Journal of the Neurological Sciences.

[118]  Colin L Masters,et al.  Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics , 2006, Journal of neurochemistry.

[119]  Klaus Fassbender,et al.  Glycerophosphocholine is elevated in cerebrospinal fluid of Alzheimer patients , 2004, Neurobiology of Aging.

[120]  M. Tolar,et al.  Neurotoxicity of the 22 kDa Thrombin-Cleavage Fragment of Apolipoprotein E and Related Synthetic Peptides Is Receptor-Mediated , 1997, The Journal of Neuroscience.

[121]  G. Ricevuti,et al.  Alzheimer disease and platelets: how’s that relevant , 2012, Immunity & Ageing.

[122]  L. Kuller,et al.  Brain cholesterol metabolism, oxysterols, and dementia. , 2013, Journal of Alzheimer's disease : JAD.

[123]  W. Klunk.  Biological Markers of Alzheimer’s Disease , 1998, Neurobiology of Aging.

[124]  P. Aisen,et al.  A lead study on oxidative stress-mediated dehydroepiandrosterone formation in serum: the biochemical basis for a diagnosis of Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[125]  C. Rowe,et al.  Blood-Borne Amyloid-β Dimer Correlates with Clinical Markers of Alzheimer's Disease , 2010, The Journal of Neuroscience.

[126]  K. Blennow,et al.  Altered blood‐brain‐barrier function in Alzheimer's disease? , 1994, Acta neurologica Scandinavica.

[127]  N. Roberts,et al.  Increased absorption of aluminium from a normal dietary intake in dementia. , 1998, Journal of inorganic biochemistry.

[128]  C. Rowe,et al.  Plasma apolipoprotein E and Alzheimer disease risk , 2011, Neurology.

[129]  Xianlin Han,et al.  Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry , 2001, Journal of neurochemistry.

[130]  P. Mcgeer,et al.  Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. , 2008, Journal of Alzheimer's disease : JAD.

[131]  J. Beard,et al.  Iron status and stores decline with age in Lewis rats. , 2000, The Journal of nutrition.

[132]  David M Holtzman,et al.  Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease , 2007, Proteomics. Clinical applications.

[133]  Kevin F Krenitsky,et al.  Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia Published, JLR Papers in Press, August 2, 2007. , 2007, Journal of Lipid Research.

[134]  J. Touchon,et al.  Combined measurement of PEDF, haptoglobin and tau in cerebrospinal fluid improves the diagnostic discrimination between alzheimer’s disease and other dementias , 2011, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[135]  H. Chertkow,et al.  Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma , 2003, Proteomics.

[136]  Sudha Seshadri,et al.  Genome-wide analysis of genetic loci associated with Alzheimer disease. , 2010, JAMA.

[137]  M. Mullan,et al.  Plasma microRNA biomarkers for detection of mild cognitive impairment , 2012, Aging.

[138]  K. Nakagawa,et al.  Amyloid β Induces Adhesion of Erythrocytes to Endothelial Cells and Affects Endothelial Viability and Functionality , 2011, Bioscience, biotechnology, and biochemistry.

[139]  Regina Berretta,et al.  Multivariate Protein Signatures of Pre-Clinical Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Plasma Proteome Dataset , 2012, PloS one.

[140]  Xianlin Han.  Lipid alterations in the earliest clinically recognizable stage of Alzheimer's disease: implication of the role of lipids in the pathogenesis of Alzheimer's disease. , 2005, Current Alzheimer research.

[141]  C. Gong,et al.  Deregulation of sphingolipid metabolism in Alzheimer's disease , 2010, Neurobiology of Aging.

[142]  A. Bush,et al.  Metals and Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.

[143]  Silva Hecimovic,et al.  Phospholipids and Alzheimer’s Disease: Alterations, Mechanisms and Potential Biomarkers , 2013, International journal of molecular sciences.

[144]  D. Aarsland,et al.  A novel blood test for the early detection of Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[145]  N. Delibaş,et al.  Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer's disease. , 2010, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements.

[146]  P. Pasqualetti,et al.  Longitudinal prognostic value of serum “free” copper in patients with Alzheimer disease , 2009, Neurology.

[147]  A. Roses,et al.  The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone , 2008 .

[148]  Simone Lista,et al.  Blood and plasma-based proteomic biomarker research in Alzheimer's disease , 2013, Progress in Neurobiology.

[149]  T. Suuronen,et al.  Clusterin: A forgotten player in Alzheimer's disease , 2009, Brain Research Reviews.

[150]  W. Markesbery,et al.  Oxidative damage in mild cognitive impairment and early Alzheimer's disease , 2007, Journal of neuroscience research.

[151]  H. Wiśniewski,et al.  Plasma amyloid β‐peptide 1–42 and incipient Alzheimer's disease , 1999 .

[152]  Monique Breteler,et al.  Identifying Early Markers of Alzheimer's Disease using Quantitative Multiplex Proteomic Immunoassay Panels , 2009, Annals of the New York Academy of Sciences.

[153]  W. D. Ehmann,et al.  Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. , 1998, Neurotoxicology.

[154]  George J. Brewer,et al.  Subclinical Zinc Deficiency in Alzheimer’s Disease and Parkinson’s Disease , 2010, American journal of Alzheimer's disease and other dementias.

[155]  E. Londos,et al.  Metal Concentrations in Plasma and Cerebrospinal Fluid in Patients with Alzheimer’s Disease , 2008, Dementia and Geriatric Cognitive Disorders.

[156]  N. Nalivaeva,et al.  Lipid Rafts and Alzheimer’s Disease: Protein-Lipid Interactions and Perturbation of Signaling , 2012, Front. Physio..

[157]  Mark R. Wilson,et al.  Potential roles of abundant extracellular chaperones in the control of amyloid formation and toxicity. , 2008, Molecular bioSystems.

[158]  J. Potempa,et al.  The serpin superfamily of proteinase inhibitors: structure, function, and regulation. , 1994, The Journal of biological chemistry.

[159]  V. Mok,et al.  Serum zinc is decreased in Alzheimer’s disease and serum arsenic correlates positively with cognitive ability , 2010, BioMetals.

[160]  M. Shoji,et al.  Plasma biomarkers of Alzheimer's disease , 2008, Current opinion in psychiatry.

[161]  S. Younkin,et al.  Serum creatinine levels correlate with plasma amyloid β protein , 2002 .

[162]  P. E. Johnson,et al.  Assessment of copper status: effect of age and gender on reference ranges in healthy adults. , 1993, Clinical chemistry.

[163]  Albert Hofman,et al.  Plasma clusterin and the risk of Alzheimer disease. , 2011, JAMA.

[164]  Joseph B. Martin,et al.  Phosphoethanolamine and ethanolamine are decreased in Alzheimer's disease and Huntington's disease , 1987, Brain Research.

[165]  H. Hinterhuber,et al.  Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein. , 2007, Drugs of today.

[166]  N. Delibaş,et al.  Malondialdehyde, superoxide dismutase, melatonin, iron, copper, and zinc blood concentrations in patients with Alzheimer disease: cross-sectional study. , 2002, Croatian medical journal.

[167]  C. Batich,et al.  In situ characterization and mapping of iron compounds in Alzheimer's disease tissue. , 2005, Journal of Alzheimer's disease : JAD.

[168]  C. Patlak,et al.  Fate of Cerebrospinal Fluid‐Borne Amyloid β‐Peptide: Rapid Clearance into Blood and Appreciable Accumulation by Cerebral Arteries , 1996, Journal of neurochemistry.

[169]  D. Boudreau,et al.  Statins in the prevention of dementia and Alzheimer's disease: A meta‐analysis of observational studies and an assessment of confounding , 2013, Pharmacoepidemiology and drug safety.

[170]  Lello Zolla,et al.  Blood-related proteomics. , 2010, Journal of proteomics.

[171]  J. D. Robertson,et al.  Copper, iron and zinc in Alzheimer's disease senile plaques , 1998, Journal of the Neurological Sciences.

[172]  A. Passaro,et al.  Trace elements and cognitive impairment: an elderly cohort study. , 2004, Archives of gerontology and geriatrics. Supplement.

[173]  C. Holmes,et al.  Systemic inflammation and Alzheimer's disease. , 2011, Biochemical Society transactions.

[174]  Madhav Thambisetty,et al.  Blood-based biomarkers of Alzheimer's disease: challenging but feasible. , 2010, Biomarkers in medicine.

[175]  D. Praticò.  The neurobiology of isoprostanes and Alzheimer's disease. , 2010, Biochimica et biophysica acta.

[176]  K. Peter,et al.  Amyloid Plaques Dissociate Pentameric to Monomeric C‐Reactive Protein: A Novel Pathomechanism Driving Cortical Inflammation in Alzheimer's Disease? , 2012, Brain pathology.

[177]  Julie A. Wood,et al.  Circulating plasmalogen levels and Alzheimer Disease Assessment Scale-Cognitive scores in Alzheimer patients. , 2010, Journal of psychiatry & neuroscience : JPN.

[178]  Susan M Resnick,et al.  Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. , 2010, Archives of general psychiatry.

[179]  J. Kaye,et al.  F2-Isoprostanes as Biomarkers of Late-onset Alzheimer’s Disease , 2007, Journal of Molecular Neuroscience.

[180]  L. Svennerholm,et al.  Membrane Lipids in the Aging Human Brain , 1991, Journal of neurochemistry.

[181]  M. Mattson,et al.  Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[182]  P. Rossini,et al.  An observational study on the influence of the APOE-ε4 allele on the correlation between ‘free’ copper toxicosis and EEG activity in Alzheimer disease , 2008, Brain Research.

[183]  C. Masters,et al.  Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples , 2013, Acta Neuropathologica.

[184]  A. Wallin,et al.  Decreased myelin lipids in Alzheimer's disease and vascular dementia , 1989, Acta neurologica Scandinavica.

[185]  H. Fukuyama,et al.  Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease , 2008, Proceedings of the National Academy of Sciences.

[186]  J. Becker,et al.  Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study , 2008, Neurology.

[187]  F. Pfrieger,et al.  Cholesterol homeostasis and function in neurons of the central nervous system , 2003, Cellular and Molecular Life Sciences CMLS.

[188]  K. Blennow,et al.  Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies , 2007, Neurology.

[189]  C. Cotman,et al.  Thrombin Attenuates Neuronal Cell Death and Modulates Astrocyte Reactivity Induced by β‐Amyloid In Vitro , 1996, Journal of neurochemistry.

[190]  K Yaffe,et al.  Midlife cardiovascular risk factors and risk of dementia in late life , 2005, Neurology.

[191]  Ashley I. Bush,et al.  Therapeutics for Alzheimer’s disease based on the metal hypothesis , 2008, Neurotherapeutics.

[192]  Magda Tsolaki,et al.  A blood gene expression marker of early Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.

[193]  M. Rattray,et al.  Gene expression profiling in human neurodegenerative disease , 2012, Nature Reviews Neurology.

[194]  Georg Kemmler,et al.  Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease , 2011, Neurobiology of Aging.

[195]  R. D'Hooge,et al.  Superoxide Dismutase Activity in Cerebrospinal Fluid of Patients with Dementia and Some Other Neurological Disorders , 1998, Alzheimer disease and associated disorders.

[196]  R. Tibshirani,et al.  Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.

[197]  H. Tammen,et al.  Peptidomic analysis of human blood specimens: Comparison between plasma specimens and serum by differential peptide display , 2005, Proteomics.

[198]  P. Liao,et al.  Proteomics analysis of plasma for potential biomarkers in the diagnosis of Alzheimer's disease , 2007, Proteomics. Clinical applications.

[199]  Christian Humpel,et al.  Identifying and validating biomarkers for Alzheimer's disease , 2011, Trends in biotechnology.

[200]  L. Ferrucci,et al.  Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment , 2010, Journal of Epidemiology & Community Health.

[201]  Blaine R. Roberts,et al.  Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease , 2014, Alzheimer's & Dementia.

[202]  R. E. Pitas,et al.  Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. , 1987, The Journal of biological chemistry.

[203]  J. Trojanowski,et al.  Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. , 2002, Archives of neurology.

[204]  Arroyo,et al.  Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers* , 1999, European journal of clinical investigation.

[205]  G. Siest,et al.  Apolipoprotein E Polymorphisms and Concentration in Chronic Diseases and Drug Responses , 2000, Clinical chemistry and laboratory medicine.

[206]  M. ChB.,et al.  Neutrophil‐lymphocyte ratio as a prognostic factor in colorectal cancer , 2005, Journal of surgical oncology.

[207]  H. Arai,et al.  Amyloid β Levels in Human Red Blood Cells , 2012, PloS one.

[208]  Blaine R. Roberts,et al.  Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.

[209]  S. Mirza,et al.  Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population , 2012, International archives of medicine.

[210]  J. Cheong,et al.  Metal transporters in intestine and brain: their involvement in metal-associated neurotoxicities , 2007, Human & experimental toxicology.

[211]  P. Rossini,et al.  ‘Free’ copper in serum of Alzheimer’s disease patients correlates with markers of liver function , 2007, Journal of Neural Transmission.

[212]  Hung Q. Dam,et al.  Blood Volume Analysis: A New Technique and New Clinical Interest Reinvigorate a Classic Study* , 2007, Journal of Nuclear Medicine Technology.

[213]  K. Blennow,et al.  Zinc and copper modulate Alzheimer Aβ levels in human cerebrospinal fluid , 2009, Neurobiology of Aging.

[214]  R. Mayeux,et al.  Meta-analysis of plasma amyloid-β levels in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[215]  B. Hyman,et al.  The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease , 2007, Neuroscience Letters.

[216]  V. Leoni.  Oxysterols as markers of neurological disease – a review , 2009, Scandinavian journal of clinical and laboratory investigation.

[217]  P. Tessari,et al.  High Abundance Proteins Depletion vs Low Abundance Proteins Enrichment: Comparison of Methods to Reduce the Plasma Proteome Complexity , 2011, PloS one.

[218]  H. Soininen,et al.  Plasma Aβ42 and Aβ40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[219]  P. Pasqualetti,et al.  Elevation of serum copper levels in Alzheimer’s disease , 2002, Neurology.

[220]  B. Winblad,et al.  Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer's disease. , 1991, Journal of neural transmission. Parkinson's disease and dementia section.

[221]  Y. Oda,et al.  Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology[S] , 2012, Journal of Lipid Research.

[222]  A. Lewis.  The role of copper in inflammatory disorders , 1984, Agents and Actions.

[223]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[224]  D. Elliott,et al.  Isoform-specific proteolysis of apolipoprotein-E in the brain , 2011, Neurobiology of Aging.

[225]  S. Younkin,et al.  Plasma amyloid β protein is elevated in late-onset Alzheimer disease families , 2008, Neurology.

[226]  Kevin Taddei,et al.  Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease , 1997, Neuroscience Letters.

[227]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[228]  I. Ferrier,et al.  Gastrointestinal absorption of aluminium in Alzheimer's disease: response to aluminium citrate. , 1992, Age and ageing.

[229]  Andrew F. Hill,et al.  Exosomes: Vehicles for the Transfer of Toxic Proteins Associated with Neurodegenerative Diseases? , 2012, Front. Physio..

[230]  R. Mayeux,et al.  Plasma ß-amyloid and cognitive decline. , 2010, Archives of neurology.

[231]  F. Giubilei,et al.  Monitoring of chemical elements and oxidative damage in patients affected by Alzheimer's disease. , 2005, Annali dell'Istituto superiore di sanita.

[232]  M. Ferretti,et al.  Does a pro-inflammatory process precede Alzheimer's disease and mild cognitive impairment? , 2011, Current Alzheimer research.

[233]  Irma-Leena Notkola,et al.  Serum Total Cholesterol, Apolipoprotein E {FC12}e4 Allele, and Alzheimer’s Disease , 1998, Neuroepidemiology.

[234]  Walter J Koroshetz,et al.  Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. , 2012, Archives of neurology.

[235]  Lars-Olof Wahlund,et al.  Structural and Quantitative Comparison of Cerebrospinal Fluid Glycoproteins in Alzheimer’s Disease Patients and Healthy Individuals , 2008, Neurochemical Research.

[236]  Dominique Drouin,et al.  Toward an Alzheimer's disease diagnosis via high-resolution blood gene expression , 2010, Alzheimer's & Dementia.

[237]  Norman J Beauchamp,et al.  White Matter Hyperintensity on Cranial Magnetic Resonance Imaging: A Predictor of Stroke , 2004, Stroke.

[238]  R. Kalaria,et al.  Alpha 1-antitrypsin and alpha 1-antichymotrypsin are in the lesions of Alzheimer's disease. , 1992, Neuroreport.

[239]  L. Launer,et al.  Do red blood cell-beta-amyloid interactions alter oxygen delivery in Alzheimer's disease? , 2008, Advances in experimental medicine and biology.

[240]  D. Selkoe,et al.  Amyloid β-peptide is produced by cultured cells during normal metabolism , 1992, Nature.

[241]  S. Rapoport,et al.  Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain , 1995, Brain Research.

[242]  Arch G Mainous,et al.  Cholesterol, transferrin saturation, and the development of dementia and Alzheimer's disease: results from an 18-year population-based cohort. , 2005, Family medicine.

[243]  Z. A. Oztürk,et al.  The Evaluation of Neutrophil-Lymphocyte Ratio in Alzheimer’s Disease , 2012, Dementia and Geriatric Cognitive Disorders.

[244]  S. Rapoport,et al.  Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer's disease prefrontal cortex. , 2011, Journal of Alzheimer's disease : JAD.

[245]  T. Okazaki,et al.  Analysis of the affinity of each haptoglobin polymer for hemoglobin by two-dimensional affinity electrophoresis. , 1997, Clinica chimica acta; international journal of clinical chemistry.

[246]  S. Scott,et al.  Cathepsin D-mediated proteolysis of apolipoprotein E: Possible role in Alzheimer’s disease , 2006, Neuroscience.

[247]  E. Zimmerman,et al.  Copper and Ceruloplasmin Abnormalities in Alzheimer’s Disease , 2010, American journal of Alzheimer's disease and other dementias.

[248]  N. Herrmann,et al.  A Meta-Analysis of Cytokines in Alzheimer's Disease , 2010, Biological Psychiatry.

[249]  N. Arnal,et al.  Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives , 2010, Brain Research.

[250]  W. D. Ehmann,et al.  Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress , 1996, Journal of the Neurological Sciences.

[251]  D. Holtzman,et al.  Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. , 2000, The Journal of clinical investigation.

[252]  Hilkka Soininen,et al.  Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. , 2005, Archives of neurology.

[253]  R. Tanzi,et al.  Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective , 2005, Cell.

[254]  J. Kaye,et al.  Safety and Acceptability of the Research Lumbar Puncture , 2005, Alzheimer disease and associated disorders.

[255]  David R. Willé,et al.  Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium‐derived factor: Two novel biomarkers of Alzheimer's disease in human plasma , 2008, Proteomics. Clinical applications.